Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,556.37
(
-0.37%
)
US TECH 100
23,360.00
(
-0.68%
)
Dow Jones
46,124.06
(
-0.18%
)
Brent Oil
95.84
(
-0.98%
)
Bitcoin
69,916.00
(
-1.39%
)
News Focus
News Focus
Post# of 257275
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122807
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 240837

Friday, 06/24/2022 10:25:28 PM

Friday, June 24, 2022 10:25:28 PM

Post# of 257275
FDA approves BMY’s Breyanzi for second-line LBCL:

https://www.businesswire.com/news/home/20220427005982/en

The approval is based on phase-3 data reported one year ago, in which Breyanzi showed statsig-superior EFS compared to SoC (#msg-164317285).

Breyanzi will compete in this newly approved indication with GILD’s Yescarta (#msg-167110232).

Breyanzi was initially FDA-approved for third-line LBCL in Feb 2021 (#msg-161552697). This is the drug at the heart of the lawsuit by former CELG shareholders (#msg-169238809).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today